<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6425">
  <stage>Registered</stage>
  <submitdate>3/11/2016</submitdate>
  <approvaldate>3/11/2016</approvaldate>
  <nctid>NCT02956850</nctid>
  <trial_identification>
    <studytitle>A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>NP39305</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Placebo
Treatment: drugs - RO7020531

Experimental: Part I: MAD in Healthy Volunteers - Healthy volunteers will receive RO7020531 (dose as selected based on safety, PK and PD data of SAD cohorts) or matching placebo orally every other day (QOD) from Day 1 through to Day 13.

Experimental: Part I: SAD in Healthy Volunteers - Healthy volunteers will receive single dose of RO7020531 or matching placebo orally on Day 1 of each cohort. A planned dose-escalation sequence for SAD is 3 mg, 10 mg, 30 mg, 90 mg, 180 mg.

Experimental: Part II: CHB Participants - CHB participants will receive RO7020531 (dose as selected based on safety, PK and PD data of MAD cohorts) or matching placebo orally QOD from Day 1 through to Day 41.


Other interventions: Placebo
Placebo matched to RO7020531 will be administered as per schedule specified in the respective arm.

Treatment: drugs: RO7020531
RO7020531 will be administered as per schedule specified in the respective arm.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Part I: Percentage of Participants With Adverse Events</outcome>
      <timepoint>From randomization up to Day 41</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part II: Percentage of Participants With Adverse Events</outcome>
      <timepoint>From randomization up to Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Part I: Maximum Observed Plasma Concentration (Cmax) of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</outcome>
      <timepoint>SAD:Predose(0-2 hours [hrs] before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24,36,48 hrs postdose. MAD:Predose(0-2 hrs before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24 hrs postdose on Day 1,13; Predose(0-2 hrs before dose),2,6,24 hrs postdose on Day 3,5,7,9,11</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part II: Percentage of B-Cells</outcome>
      <timepoint>Predose (0-2 hrs before dose) on Day 21; 24 hrs postdose on Day 41; Week 9 and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part II: Percentage of NK Cells</outcome>
      <timepoint>Predose (0-2 hrs before dose) on Day 21; 24 hrs postdose on Day 41; Week 9 and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part II: Percentage of Myeloid Cells</outcome>
      <timepoint>Predose (0-2 hrs before dose) on Day 21; 24 hrs postdose on Day 41; Week 9 and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part II: Percentage of Plasmacytoid Dendritic Cells (pDCs)</outcome>
      <timepoint>Predose (0-2 hrs before dose) on Day 21; 24 hrs postdose on Day 41; Week 9 and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part II: Cmax of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</outcome>
      <timepoint>Predose (0-2 hrs before dose), 0.25, 1, 2, 4, 6, 8, 24 hrs postdose on Days 1, 41; Predose (0-2 hrs before dose), 2-4 hrs postdose on Days 3, 7, 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I: Time to Reach Cmax (Tmax) of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</outcome>
      <timepoint>SAD: Predose(0-2 hrs before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24,36,48 hrs postdose. MAD: Predose (0-2 hrs before dose), 0.25,0.5,1,1.5,2,3,4,6,8,12,18,24 hrs postdose on Days 1,13; Predose (0-2 hrs before dose), 2,6,24 hrs postdose on Days 3,5,7,9,11</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part II: Tmax of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</outcome>
      <timepoint>Predose (0-2 hrs before dose), 0.25, 1, 2, 4, 6, 8, 24 hrs postdose on Days 1, 41; Predose (0-2 hrs before dose), 2-4 hrs postdose on Days 3, 7, 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUCinf) of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</outcome>
      <timepoint>SAD: Predose(0-2 hrs before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24,36,48 hrs postdose. MAD: Predose (0-2 hrs before dose), 0.25,0.5,1,1.5,2,3,4,6,8,12,18,24 hrs postdose on Days 1,13; Predose (0-2 hrs before dose), 2,6,24 hrs postdose on Days 3,5,7,9,11</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part II: AUCinf of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</outcome>
      <timepoint>Predose (0-2 hrs before dose), 0.25, 1, 2, 4, 6, 8, 24 hrs postdose on Days 1, 41; Predose (0-2 hrs before dose), 2-4 hrs postdose on Days 3, 7, 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I: Area Under the Plasma Concentration Versus Time Curve up to the Last Measurable Concentration (AUClast) of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</outcome>
      <timepoint>SAD: Predose(0-2 hrs before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24,36,48 hrs postdose. MAD: Predose (0-2 hrs before dose), 0.25,0.5,1,1.5,2,3,4,6,8,12,18,24 hrs postdose on Days 1,13; Predose (0-2 hrs before dose), 2,6,24 hrs postdose on Days 3,5,7,9,11</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part II: AUClast of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</outcome>
      <timepoint>Predose (0-2 hrs before dose), 0.25, 1, 2, 4, 6, 8, 24 hrs postdose on Days 1, 41; Predose (0-2 hrs before dose), 2-4 hrs postdose on Days 3, 7, 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I: Half-Life (t1/2) of RO7020531; and its Metabolites Including RO7011785, RO7018822 and RO7033805</outcome>
      <timepoint>SAD: Predose(0-2 hrs before dose),0.25,0.5,1,1.5,2,3,4,6,8,12,18,24,36,48 hrs postdose. MAD: Predose (0-2 hrs before dose), 0.25,0.5,1,1.5,2,3,4,6,8,12,18,24 hrs postdose on Days 1,13; Predose (0-2 hrs before dose), 2,6,24 hrs postdose on Days 3,5,7,9,11</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part II: t1/2 of RO7020531; and its Metabolites including RO7011785, RO7018822 and RO7033805</outcome>
      <timepoint>Predose (0-2 hrs before dose), 0.25, 1, 2, 4, 6, 8, 24 hrs postdose on Days 1, 41; Predose (0-2 hrs before dose), 2-4 hrs postdose on Days 3, 7, 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I: Total Amount of RO7020531, RO7011785, RO7018822 and RO7033805 in Urine</outcome>
      <timepoint>0 to 24 hrs post-dose on Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma Neopterin Levels</outcome>
      <timepoint>SAD: Days 1, 2, 3, 5, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma Interferon (INF)-alpha Levels</outcome>
      <timepoint>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma Interferon Gamma-Inducible Protein 10 (IP-10) Levels</outcome>
      <timepoint>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma Tumor Necrosis Factor (TNF)-alpha Levels</outcome>
      <timepoint>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma IL-6 Levels</outcome>
      <timepoint>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma IL-10 Levels</outcome>
      <timepoint>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma IL-12p40 Levels</outcome>
      <timepoint>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma Interferon-Stimulated Gene (ISG) 15 messenger Ribonucleic Acid (mRNA) Levels</outcome>
      <timepoint>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma Oligoadenylate Synthetase (OAS)-1 mRNA Levels</outcome>
      <timepoint>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma Myxovirus Resistance 1 gene (MX1) mRNA Levels</outcome>
      <timepoint>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part I and II: Pharmacodynamics: Plasma Toll-Like Receptor (TLR) 7 mRNA Levels</outcome>
      <timepoint>SAD: Days 1, 8. MAD: Days 1, 3, 5, 7, 13, 20. Part II: Days 1, 3, 7, 21, 41 (detailed timeframe is provided in outcome measure description)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part II: Percentage of T-Cells</outcome>
      <timepoint>Predose (0-2 hrs before dose) on Day 21; 24 hrs postdose on Day 41; Week 9 and Week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Part 1: SAD and MAD in Healthy Volunteers

          -  A Body Mass Index (BMI) between 18 to 30 kilograms per square meter (kg/m^2),
             inclusive

          -  Non-smokers, or use of less than (&lt;) 10 cigarettes (or equivalent nicotine-containing
             product) per day

          -  Negative Anti-Nuclear Antibody (ANA) test; or positive with dilutions not greater than
             1:40 and with no associated history or symptoms of potential connective tissue disease
             or other immune-mediated diseases

        Part 2: CHB Participants

          -  A BMI between 18 to 32 kg/m^2, inclusive

          -  CHB infection (positive test for Hepatitis B surface antigen [HBsAg] for more than 6
             months prior to randomization)

          -  HBsAg detectable at screening

          -  Hepatitis B Virus (HBV) deoxyribonucleic acid (DNA) &lt;90 international units per
             milliliter (IU/mL) for at least 6 months prior to randomization; HBV DNA &lt;90 IU/mL at
             screening by Roche Cobas assay

          -  Negative ANA test; or positive with dilutions not greater than 1:40 and with no
             associated history or symptoms of potential connective tissue disease or other
             immune-mediated diseases

          -  Liver biopsy, fibroscanÂ® or equivalent elastography test obtained within 6 months
             prior to randomization demonstrating liver disease consistent with chronic HBV
             infection with absence of cirrhosis and absence of extensive bridging fibrosis
             (cirrhosis or extensive bridging fibrosis are defined as greater than or equal to
             (&gt;/=) Metavir 3, recommended cut-off for fibroscan 8.5 kilopascals [kPa])

          -  On treatment with tenofovir, entecavir, adefovir, or telbivudine, either as single
             agents or in combination, for at least 6 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Part 1: SAD and MAD in Healthy Volunteers

          -  History of immunologically mediated disease (e.g., inflammatory bowel disease,
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic
             anemia, scleroderma, severe psoriasis, rheumatoid arthritis, multiple sclerosis, or
             any other autoimmune disease); clinically significant thyroid disease, psychiatric
             disease, acute infection (e.g., influenza), gastrointestinal (GI) disease (including
             inflammatory bowel disease, peptic ulcer disease, GI hemorrhage)

          -  Any clinically significant concomitant disease or condition that could interfere with,
             or for which the treatment of might interfere with, the conduct of the study, or that
             would, in the opinion of the Investigator, pose an unacceptable risk to the
             participant in this study

          -  Positive Hepatitis A virus antibody (HAV Ab IgM), HBsAg, Hepatitis C antibody (HCV
             Ab), or positive for human immunodeficiency virus (HIV) at screening

          -  History of clinically significant thyroid disease; also, participants with clinically
             significant elevated thyroid-stimulating hormone (TSH) concentrations at screening

          -  Positive results for anti-mitochondrial antibody (AMA), anti-smooth muscle antibody
             (ASMA) or thyroid peroxidase antibody

        Part 2: CHB Participants

          -  History of liver cirrhosis

          -  History or other evidence of bleeding from esophageal varices

          -  Decompensated liver disease (e.g., Child-Pugh Class B or C clinical classification or
             clinical evidence such as ascites or varices)

          -  History or other evidence of a medical condition associated with chronic liver disease
             other than HBV infection (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver
             disease, toxin exposure, thalassemia, nonalcoholic steato-hepatitis, etc.)

          -  Documented history or other evidence of metabolic liver disease within one year of
             randomization

          -  Positive test for Hepatitis A virus (IgM anti-HAV), HCV, Hepatitis D or HIV

          -  History of or suspicion of hepatocellular carcinoma or alpha fetoprotein &gt;/=13
             nanograms per milliliter (ng/mL) at screening

          -  History of immunologically mediated disease (e.g., inflammatory bowel disease,
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic
             anemia, scleroderma, severe psoriasis, rheumatoid arthritis, multiple sclerosis, or
             any other autoimmune disease); clinically significant thyroid disease, psychiatric
             disease, acute infection (e.g., influenza), GI disease (including inflammatory bowel
             disease, peptic ulcer disease, GI hemorrhage)

          -  History of organ transplantation

          -  Clinically significant thyroid disease; also, participants with clinically significant
             elevated TSH concentrations at screening

          -  Positive results for AMA, ASMA or thyroid peroxidase antibody</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>12/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>110</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>24/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This sponsor-open, investigator- and participant-blinded, multi-center study will assess the
      safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy
      participants and in participants with chronic hepatitis B. Part I will be conducted in two
      portions: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) which will include
      only healthy volunteers. Part II will commence after completion of the MAD portion of Part I
      and will include only Chronic Hepatitis B (CHB) participants.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02956850</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Reference Study ID Number: NP39305 www.roche.com/about_roche/roche_worldwide.htm</name>
      <address />
      <phone>888-662-6728 (U.S. and Canada)</phone>
      <fax />
      <email>global-roche-genentech-trials@gene.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>